drugset
drugset / Trial / NCT00979953

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

NCT00979953 ↗

Phase 2 Completed 408 enrolled Merck & Co., Inc. Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747 versus placebo in relieving pain in participants with osteoarthritis of the knee.

Timeline

Start
2009-10
Primary completion
2010-04
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ADL5747 Small molecule 150 mg Oral
Subject ADL5859 Small molecule 150 mg Oral
Comparator Oxycodone Other / unclassified 20 mg Oral

Indications

osteoarthritis, knee